P R Breeze1, C Thomas1, H Squires1, A Brennan1, C Greaves2, P J Diggle3,4, E Brunner5, A Tabak5, L Preston1, J Chilcott1. 1. School of Health and Related Research, University of Sheffield, Sheffield, UK. 2. Medical School, University of Exeter, Exeter, UK. 3. Medical School, Lancaster University, Lancaster, UK. 4. Institute of Infection and Global Health, University of Liverpool, Liverpool, UK. 5. Epidemiology & Public Health, University College London, London, UK.
Abstract
AIMS: To develop a cost-effectiveness model to compare Type 2 diabetes prevention programmes targeting different at-risk population subgroups with a lifestyle intervention of varying intensity. METHODS: An individual patient simulation model was constructed to simulate the development of diabetes in a representative sample of adults without diabetes from the UK population. The model incorporates trajectories for HbA1c , 2-h glucose, fasting plasma glucose, BMI, systolic blood pressure, total cholesterol and HDL cholesterol. Patients can be diagnosed with diabetes, cardiovascular disease, microvascular complications of diabetes, cancer, osteoarthritis and depression, or can die. The model collects costs and utilities over a lifetime horizon. The perspective is the UK National Health Service and personal social services. We used the model to evaluate the population-wide impact of targeting a lifestyle intervention of varying intensity to six population subgroups defined as high risk for diabetes. RESULTS: The intervention produces 0.0003 to 0.0009 incremental quality-adjusted life years and saves up to £1.04 per person in the general population, depending upon the subgroup targeted. Cost-effectiveness increases with intervention intensity. The most cost-effective options are to target individuals with HbA1c > 42 mmol/mol (6%) or with a high Finnish Diabetes Risk (FINDRISC) probability score (> 0.1). CONCLUSION: The model indicates that diabetes prevention interventions are likely to be cost-effective and may be cost-saving over a lifetime. In the model, the criteria for selecting at-risk individuals differentially impact upon diabetes and cardiovascular disease outcomes, and on the timing of benefits. These findings have implications for deciding who should be targeted for diabetes prevention interventions.
AIMS: To develop a cost-effectiveness model to compare Type 2 diabetes prevention programmes targeting different at-risk population subgroups with a lifestyle intervention of varying intensity. METHODS: An individual patient simulation model was constructed to simulate the development of diabetes in a representative sample of adults without diabetes from the UK population. The model incorporates trajectories for HbA1c , 2-h glucose, fasting plasma glucose, BMI, systolic blood pressure, total cholesterol and HDL cholesterol. Patients can be diagnosed with diabetes, cardiovascular disease, microvascular complications of diabetes, cancer, osteoarthritis and depression, or can die. The model collects costs and utilities over a lifetime horizon. The perspective is the UK National Health Service and personal social services. We used the model to evaluate the population-wide impact of targeting a lifestyle intervention of varying intensity to six population subgroups defined as high risk for diabetes. RESULTS: The intervention produces 0.0003 to 0.0009 incremental quality-adjusted life years and saves up to £1.04 per person in the general population, depending upon the subgroup targeted. Cost-effectiveness increases with intervention intensity. The most cost-effective options are to target individuals with HbA1c > 42 mmol/mol (6%) or with a high Finnish Diabetes Risk (FINDRISC) probability score (> 0.1). CONCLUSION: The model indicates that diabetes prevention interventions are likely to be cost-effective and may be cost-saving over a lifetime. In the model, the criteria for selecting at-risk individuals differentially impact upon diabetes and cardiovascular disease outcomes, and on the timing of benefits. These findings have implications for deciding who should be targeted for diabetes prevention interventions.
Authors: Natalia Olchanski; David van Klaveren; Joshua T Cohen; John B Wong; Robin Ruthazer; David M Kent Journal: Acta Diabetol Date: 2021-01-30 Impact factor: 4.280
Authors: Viviana Bauman; Aviva H Ariel-Donges; Eliza L Gordon; Michael J Daniels; Dandan Xu; Kathryn M Ross; Marian C Limacher; Michael G Perri Journal: BMJ Open Diabetes Res Care Date: 2019-05-28
Authors: Sundar S Shrestha; Amanda A Honeycutt; Wenya Yang; Ping Zhang; Olga A Khavjou; Diana C Poehler; Simon J Neuwahl; Thomas J Hoerger Journal: Diabetes Care Date: 2018-10-10 Impact factor: 19.112
Authors: Chloe Thomas; Alan Brennan; Edward Goka; Hazel Y Squires; Gilly Brenner; David Bagguley; Helen Buckley Woods; Michael Gillett; Joanna Leaviss; Mark Clowes; Laura Heathcote; Katy Cooper; Penny Breeze Journal: BMJ Open Date: 2020-09-10 Impact factor: 2.692
Authors: Penny Breeze; Chloe Thomas; Praveen Thokala; Louise Lafortune; Carol Brayne; Alan Brennan Journal: Med Decis Making Date: 2020-09-19 Impact factor: 2.583